John C Larosa

Learn More
BACKGROUND Previous trials have demonstrated that lowering low-density lipoprotein (LDL) cholesterol levels below currently recommended levels is beneficial in patients with acute coronary syndromes. We prospectively assessed the efficacy and safety of lowering LDL cholesterol levels below 100 mg per deciliter (2.6 mmol per liter) in patients with stable(More)
BACKGROUND Levels of atherogenic lipoproteins achieved with statin therapy are highly variable, but the consequence of this variability for cardiovascular disease risk is not well-documented. OBJECTIVES The aim of this meta-analysis was to evaluate: 1) the interindividual variability of reductions in low-density lipoprotein cholesterol (LDL-C),(More)
OBJECTIVE The Treating to New Targets study showed that intensive lipid-lowering therapy with atorvastatin 80 mg/day provides significant clinical benefit beyond that afforded by atorvastatin 10 mg/day in patients with stable coronary heart disease (CHD). The objective of our study was to investigate whether similar benefits of high-dose intensive(More)
CONTEXT Lowering low-density lipoprotein cholesterol (LDL-C) is known to reduce risk of recurrent coronary heart disease in middle-aged men. However, this effect has been uncertain in elderly people and women. OBJECTIVE To estimate the risk reduction of coronary heart disease and total mortality associated with statin drug treatment, particularly in(More)
Many epidemiologic studies and clinical trials have demonstrated the linear relation between elevated serum levels of low-density lipoprotein (LDL) cholesterol and the risk for coronary heart disease. Conversely, for each 1% reduction in LDL cholesterol in clinical trials, there is a corresponding 1% reduction in coronary heart disease risk. Although the(More)
1. Cholesterol management in high-risk patients without heart disease. When is lipid-lowering medication warranted for primary prevention? Grundy SM. 3. The role of cholesterol management in coronary disease risk reduction in elderly patients. [PubMed-indexed for MEDLINE]Related citations 4. Mapping a gene involved in regulating dietary cholesterol(More)
Twenty-four obese but otherwise normal men and women were followed for: Two weeks on their usual food intake; eight weeks on a high-protein, low-carbohydrate diet; and then again for two weeks on their usual diet. During this time, several metabolic parameters were measured bimonthly. The high-protein, low-carbohydrate dieting resulted in substantial weight(More)
CONTEXT The associations of low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and apolipoprotein B (apoB) levels with the risk of cardiovascular events among patients treated with statin therapy have not been reliably documented. OBJECTIVE To evaluate the relative strength of the associations of LDL-C,(More)